Business
AI suggests Australia may have backed a COVID-19 vaccine winner – The Australian Financial Review
Even the COVID-19 vaccines in phase three clinical trials have only a 20 per cent chance of success, an Australian AI healthcare data company says.
Some of the positive factors supporting the vaccine were the number of trial locations (approximately 20), trial participants (more than 12,000) and its randomised design. The chance of the trial succeeding could be improved by increasing the number of countries where the trial operates.
Ms Gallaher, who has spent 30 years in the biotech and pharmaceutical industry, and has also taken part in clinical trials, hoped the research would help governments and investors around the globe to pick which…
-
Noosa News16 hours agoSee inside the hidden suburbs where Queensland investors really live
-
Noosa News16 hours agoBusiness expo sparks inspiration and connection
-
Business14 hours agoWhy it’s time to buy Domino’s, Flight Centre, and WiseTech shares
-
Noosa News15 hours agoThe best new books released in August, from Toni Jordan, Rhett Davis and more